Mark L McLaughlin
Overview
Explore the profile of Mark L McLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huynh A, Cohen A, Doligalski M, Casagni T, Moberg V, Huang X, et al.
Cancer Res Commun
. 2024 Sep;
4(11):2877-2887.
PMID: 39320054
Significance: Human TLR2 is broadly expressed among pancreatic adenocarcinomas, and the highly specific TLR2L-800 fluorescence molecular imaging agent has potential for use in fluorescence-guided surgery to increase R0 margins and...
2.
Jain P, Badger D, Liang Y, Gebhard A, Santiago D, Murray P, et al.
Pept Sci (Hoboken)
. 2022 Jul;
113(3):e24199.
PMID: 35859761
HYD1 is an all D-amino acid linear 10-mer peptide that was discovered by one-bead-one-compound screening. HYD1 has five hydrophobic amino acids flanked by polar amino acids. Alanine scanning studies showed...
3.
Tafreshi N, Kil H, Pandya D, Tichacek C, Doligalski M, Budzevich M, et al.
ACS Pharmacol Transl Sci
. 2021 Apr;
4(2):953-965.
PMID: 33860213
Lipophilicity is explored in the biodistribution (BD), pharmacokinetics (PK), radiation dosimetry (RD), and toxicity of an internally administered targeted alpha-particle therapy (TAT) under development for the treatment of metastatic melanoma....
4.
Tichacek C, Tafreshi N, Kil H, Engelman R, Doligalski M, Budzevich M, et al.
Mol Pharm
. 2020 Sep;
17(11):4180-4188.
PMID: 32960613
Targeted α particle therapy (TAT) is ideal for treating disease while minimizing damage to surrounding nontargeted tissues due to short path length and high linear energy transfer (LET). We developed...
5.
Tafreshi N, Doligalski M, Tichacek C, Pandya D, Budzevich M, El-Haddad G, et al.
Molecules
. 2019 Nov;
24(23).
PMID: 31779154
Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface...
6.
Tafreshi N, Tichacek C, Pandya D, Doligalski M, Budzevich M, Kil H, et al.
J Nucl Med
. 2019 Feb;
60(8):1124-1133.
PMID: 30733316
New effective therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a median survival of less than 1 y. The melanocortin 1 receptor (MC1R)...
7.
Khabibullin A, Karolak A, Budzevich M, McLaughlin M, Morse D, Woods L
Medchemcomm
. 2018 Aug;
9(7):1155-1163.
PMID: 30109003
The successful delivery of toxic cargo directly to tumor cells is of primary importance in targeted (α) particle therapy. Complexes of radioactive atoms with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelating agent...
8.
Gebhard A, Jain P, Nair R, Emmons M, Argilagos R, Koomen J, et al.
Mol Cancer Ther
. 2013 Sep;
12(11):2446-58.
PMID: 24048737
Our laboratory recently reported that treatment with the d-amino acid containing peptide HYD1 induces necrotic cell death in multiple myeloma cell lines. Because of the intriguing biological activity and promising...
9.
Drake B, Morris J, McLaughlin M, Fronczek F, Watkins S
Acta Crystallogr Sect E Struct Rep Online
. 2012 Aug;
68(Pt 8):o2540-1.
PMID: 22904973
In the title co-crystal, C(22)H(16)O(10)·C(22)H(18)O(8), the independent tetra-methyl 9,10-dihydro-9,10-dioxoanthracene-2,3,6,7-tetra-carboxyl-ate, (I), and tetra-methyl anthracene-2,3,6,7-tetra-carboxyl-ate, (II), components occupy separate crystallographic inversion centers. In (II), the dihedral angles between the mean aromatic plane...
10.
Emmons M, Gebhard A, Nair R, Baz R, McLaughlin M, Cress A, et al.
Mol Cancer Ther
. 2011 Oct;
10(12):2257-66.
PMID: 21980133
We recently reported that the β1 integrin antagonist, referred to as HYD1, induces necrotic cell death in myeloma cell lines as a single agent using in vitro and in vivo...